Eltrombopag Production Cost Reports

The report provides a detailed analysis essential for establishing an Eltrombopag production plant. It encompasses all critical aspects necessary for Eltrombopag production, including the cost of Eltrombopag production, Eltrombopag plant cost, Eltrombopag production costs, and the overall Eltrombopag production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Eltrombopag production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Eltrombopag is an active pharmaceutical ingredient (API), available in the form of its olamine salt. It mainly has industrial applications within pharmaceutical production. It is known as a thrombopoietin receptor agonist for treating thrombocytopenia and related blood disorders. Additionally, it is utilised to produce treatments targeting thrombocytopenia associated with chronic immune thrombocytopenia (ITP), hepatitis C, and severe aplastic anaemia (SAA).

The market demand for Eltrombopag is driven by the increasing global prevalence of thrombocytopenia-linked conditions such as immune thrombocytopenic purpura (ITP), severe aplastic anaemia (SAA), hepatitis C-associated thrombocytopenia, and emerging chemotherapy-induced cases. Additionally, ageing populations, better diagnostics, and rising haematological disorder incidences boost the market growth. Generic drug entries, including formulations like Eltrombopag Viatris, improve affordability and market penetration, especially in emerging regions like Asia-Pacific, amid healthcare infrastructure investments and growing spending, which contributes to the demand.

Moreover, expanded clinical indications through R&D in oncology and myelodysplastic syndromes (MDS), as well as endorsements from medical societies like ASH and EHA, propel the market expansion. Industrial eltrombopag procurement is influenced by factors such as purity levels, polymorphism stability, and emerging R&D needs for bulk production or formulation, with buyers prioritising suppliers offering consistent allocation, bioequivalence, and cost-effective export capabilities.

Raw Material for Eltrombopag Production

According to the Eltrombopag production plant project report, the various raw materials for Eltrombopag production include 2-bromophenol, sodium nitrate, and sulfuric acid.

Production Process of Eltrombopag

The extensive Eltrombopag production cost report consists of the following major industrial production process:

1. Production via a multi-step organic synthesis: The production process of Eltrombopag starts with the nitration of 2-bromophenol using sodium nitrate and sulfuric acid in water to yield 2-bromo-6-nitrophenol. In the next step, the resulting compound undergoes etherification with iodomethane and potassium carbonate to form 2-bromo-6-nitroanisole, followed by Suzuki coupling with 3-carboxyphenylboronic acid to obtain an intermediate, which is demethylated using 48% aqueous hydrobromic acid in refluxing acetic acid to give another intermediate. Nitro reduction of this intermediate with H2 and Pd/C catalysis yields the amine intermediate, which is diazotised using sodium nitrite and hydrochloric acid. Finally, the resulting diazo salt couples with a pyrazolone derivative like 2-(3,4-dimethylphenyl)-5-methyl-1H-pyrazol-3(2H)-one to form the Eltrombopag base.

Properties of Eltrombopag

Eltrombopag, commonly as its olamine salt (C29H36N6O6, molecular weight 564.65 g/mol), appears as a red-brown crystalline solid or deep red powder with low aqueous solubility. It is practically insoluble from pH 1-7.4 and sparingly soluble in water, yet freely soluble in methanol and DMSO at concentrations exceeding 14 mg/mL upon warming. The free base form (C25H22N4O4, molecular weight 442.47 g/mol) features 7 hydrogen bond donors and 11 acceptors, supporting its BCS Class IV classification due to poor solubility and permeability. It has a characteristic odour and stability under controlled storage without decomposition, though incompatible with strong oxidants. It remains stable at -20 degree Celsius in sealed conditions, with industrial formulations mitigating polymorphism and hygroscopicity through excipients to ensure tablet integrity for up to 36 months at 25 degree Celsius/60% RH.